| Description | Trevogrumab (REGN-1033), a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as muscle growth inhibitor), is currently under investigation for the treatment of sarcopenia, characterized by wasting atrophy, chronic diseases, and alterations in dietary and nutritional intake [1]. |
| Synonyms | REGN-1033 |
| molecular weight | N/A |
| CAS | 1429201-24-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |